Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: A retrospective study
Journal of the Egyptian National Cancer Institute · 2011
DOI: 10.1016/j.jnci.2011.07.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Egyptian National Cancer Institute, 2011. Verfasst von Thoraya Abdelhamid und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt. thorayaabdelhamid@yahoo.com. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of NHL in Egypt. It represents about 49% of NHL presenting to the National Cancer Institute (NCI), Cairo University. CHOP regimen is the standard treatment used for NHL since the 1970s with only 30-40% overall survival. Recently, integration of Rituximab became a standard of care for patients with DLBCL. However, its widespread use in developing countries is still limited by the lack of financial coverage. Clinical prognostic factors, as well as the pathological markers, are mandatory to individualize treatment. AIM: The aim of the study was to evaluate the clinical risk stratification models including the age adjusted International prognostic index (aaIPI), patients profile and dose intensity (DI) of Cyclophosphamide and Doxorubicin as effective tools for predicting the outcome and prognosis of our DLBCL patients treated with first line CHOP regimen. PATIENTS AND METHODS: This retrospective study included 224 patients with diffuse large B cell lymphoma who were treated with 3-8 cycles of CHOP regimen at the Medical Oncology Department, NCI, Cairo University during the time period from 1999 to 2006. RESULTS: One hundred and seventy-eight patients (79.5%) achieved CR after the CHOP regimen with an observation period of 51 months. The median survival time was 12 months. The OS and DFS at 2 years were 82% and 68.8%, respectively. The univariate analysis of predictive factors for response to treatment showed that the CR rate was significantly affected by aa-IPI and its elements (performance status, stage & LDH), extranodal lesions and DI of Cyclophosphamide and Doxorubicin. The CR rate was 96.9%, 91.2%, 73.9% and 55.6% in cases with aa-IPI 0, 1, 2 and 3, respectively (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt. thorayaabdelhamid@yahoo.com
Zitieren
APA
Abdelhamid, T., Samra, M., Ramadan, H., Mehessin, M., & Mokhtar, N. (2011). Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: A retrospective study. Journal of the Egyptian National Cancer Institute. https://doi.org/10.1016/j.jnci.2011.07.003
Vancouver
Abdelhamid T, Samra M, Ramadan H, Mehessin M, Mokhtar N. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: A retrospective study. Journal of the Egyptian National Cancer Institute. 2011. doi:10.1016/j.jnci.2011.07.003
BibTeX
@article{Abdelhamid2011,
author = {Abdelhamid, Thoraya and Samra, Mohamed and Ramadan, Hanan and Mehessin, Marowa and Mokhtar, Nadia},
title = {Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: A retrospective study},
journal = {Journal of the Egyptian National Cancer Institute},
year = {2011},
doi = {10.1016/j.jnci.2011.07.003}
}
EUVIMED